Bonk (NASDAQ:BNKK) Releases Earnings Results

Posted by Brenda Bartman on May 14th, 2026

Bonk (NASDAQ:BNKK – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.23) earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $0.79 million during the quarter. Bonk had a negative return on equity of 208.29% and a negative net margin of 1,993.19%.

Bonk Trading Down 2.2%

NASDAQ:BNKK opened at $2.20 on Thursday. The firm’s 50-day simple moving average is $2.68. The company has a market capitalization of $17.31 million, a PE ratio of -0.29 and a beta of 1.97. Bonk has a 52 week low of $2.15 and a 52 week high of $46.90.

Insider Buying and Selling

In other Bonk news, Director Mitchell Austin Rudy purchased 31,055 shares of the firm’s stock in a transaction on Thursday, April 9th. The shares were acquired at an average cost of $2.82 per share, with a total value of $87,575.10. Following the completion of the acquisition, the director directly owned 44,198 shares in the company, valued at $124,638.36. The trade was a 236.29% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 51.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Bonk

Institutional investors and hedge funds have recently bought and sold shares of the business. State Street Corp bought a new stake in Bonk during the fourth quarter valued at about $33,000. Steward Partners Investment Advisory LLC bought a new stake in Bonk during the fourth quarter valued at about $37,000. Jane Street Group LLC bought a new stake in Bonk during the fourth quarter valued at about $96,000. Finally, Geode Capital Management LLC bought a new stake in Bonk during the fourth quarter valued at about $128,000. 12.55% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded Bonk from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

View Our Latest Research Report on BNKK

About Bonk

(Get Free Report)

Safety Shot, Inc, a wellness and functional beverage company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners. The company was formerly known as Jupiter Wellness, Inc and changed its name to Safety Shot, Inc in September 2023.